lilly glp 1 drug FDA approves new weight-loss pill, Foundayo Novo, Lilly weight-loss drugs should
Description
has served as a consultant for Novo Nordisk and Viking Therapeutics, and serves as a national lead investigator or on the executive committee for trials conducted by AstraZeneca and Novo Nordisk

Source: Snchez-Garrido MA, et al

Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents
And more pathways to Medicare coverage could open up if these drugs gain FDA approval for other uses

Ultimately, there is a pressing need to understand whether the beneficial indirect effects of GLP-1RA medications on pancreatic diseases, including PDAC (e.g., weight loss), are negated by direct effects on the pancreas
